期刊文献+

阿托伐他汀抗家兔内膜损伤后动脉粥样硬化的实验研究 被引量:2

Experimental study of effect of atorvastatin on atherosclerosis in an rabbit intimal injury model
下载PDF
导出
摘要 目的探讨阿托伐他汀抗动脉粥样硬化的作用。方法将29只新西兰白兔随机分为正常组7例、病理组7例、用药5周组7例及用药9周组8例。实验前后抽血测定血脂全套,主动脉标本用作普通光镜、透射电镜及斑块面积检查。结果阿托伐他汀显著降低胆固醇(TC)、甘油三酯(TG)及低密度脂蛋白胆固醇(LDL-C),升高高密度脂蛋白胆固醇(HDL-C),组织病理学检查显示用药组血管内膜厚度、内膜中泡沫细胞、平滑肌细胞(SMC)明显减少,未见合成型SMC,用药9周组与病理组相比斑块面积减小。结论阿托伐他汀具有明显的抗动脉粥样硬化的作用。 Objective To investigate the effect of atorvastatin on atherosclerosis.Methods Twenty-nine healthy New Zealand white rabbits were randomly separated into 4 groups: normal group (n=7),pathological group(n=7)(2.5 mg·kg-1·d-1)and 9 week atorvastatin treated group (n=8)( 2.5 mg·kg-1·d-1).Total cholesterol (TC),high density lipoprotein cholesterol (HDL-C),low density lipoprotein cholesterol (LDL-C)and triglyceride(TG)were assayed at the onset and the end of the study.The arteries were processed for hematoxylin-eosin staining, scanning electron microscopy and measurement of plaque area.Results Atorvastatin reduced serum TC,LDL-C,and TG,while elevated serum HDL-C.Histopathologic examination showed the treated group had a remarkably decreased intimal thickness,intimal foam cells and smooth muscle cells (SMC),but without synthetic SMC.The plaque area was reduced in 9 week treated group(P<0.05).Conclusion Atorvastatin has antiatherogenic effect.
出处 《中国药物与临床》 CAS 2005年第5期339-342,共4页 Chinese Remedies & Clinics
关键词 阿托伐他汀 家兔 内膜损伤 动脉粥样硬化 组织病理学 胆固醇 动脉硬化 Arteriosclerosis Cholesterol Rabbits Atorvastatin
  • 相关文献

参考文献11

  • 1Shepherd J,Cobbe SM,Ford I,et al. For the west of Scotland Coronary Prevention Study Group:prevention of coronary heart disease with provastatin in men with hypercholesterolemia. New Engl J Med,1995,333:1301-1307.
  • 2Pedersen TR,Kjekshus J,Berg K,et al. Scandinavian trial of cholesterol lowering in 444 patients with coronary heart disease:the Scandinavian Simvastatin Survival Study (4S).Lancet, 1994,343:1383-1389.
  • 3Sacks FM,Pfeffer MA,Moye L,et al.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.New Engl J Med,1996,335:1001-1009.
  • 4Blankenhorn DH,Azen SP,Kramsh DM,et al. Coronary angiographic changes with lovastatin therapy:the Monitored Atherosclerosis Regression Study (MARS).Am Int Med,1993,119:969-976.
  • 5Oliver MF, de Feyter PJ,Lubsen J,et al. MAAS investigators: effects of simavastatin on coronary atheroma:the Multicentre Anti-Atheroma Study (MAAS).Lancet, 1994, 344:633-638.
  • 6Jukema JW,Bruschke AVG,van Broven AJ,et al. Interuniversity Cardiology Institute Utrecht,the Nethertands:effect of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol level,the Regression Grouwth Evaluation Statin Study (REGRESS).Circulation, 1995,91:2528-2540.
  • 7Tall AR.Plasma lipid transfer protein.Annu Rev Biochem, 1995,64:235-257.
  • 8Lea AP,Mc Tavish D.Atorvastatin,a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs,1997,53:828-847.
  • 9Heinomen TM,Stein E,Weiss SR,et al.The lipid-lowering effect of atorvastatin,a new HMG-CoA reductase inhibitor: result of a double-masked study. Clin Ther, 1996,18:853-863.
  • 10Marais AD,Naoumova RP,Firth JC,et al. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesteromia. J Lipid Res, 1997, 38:2071-2078.

同被引文献19

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部